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There is sexual dimorphism of skeletal muscle, the most obvious feature being the larger muscle mass of men. The molecular
basis for this difference has not been clearly defined. To identify genes that might contribute to the relatively greater
muscularity of men, we compared skeletal muscle gene expression profiles of 15 normal men and 15 normal women by using
comprehensive oligonucleotide microarrays. Although there were sex-related differences in expression of several hundred
genes, very few of the differentially expressed genes have functions that are obvious candidates for explaining the larger
muscle mass of men. The men tended to have higher expression of genes encoding mitochondrial proteins, ribosomal
proteins, and a few translation initiation factors. The women had .2-fold greater expression than the men (P,0.0001) of two
genes that encode proteins in growth factor pathways known to be important in regulating muscle mass: growth factor
receptor-bound 10 (GRB10) and activin A receptor IIB (ACVR2B). GRB10 encodes a protein that inhibits insulin-like growth
factor-1 (IGF-1) signaling. ACVR2B encodes a myostatin receptor. Quantitative RT-PCR confirmed higher expression of GRB10
and ACVR2B genes in these women. In an independent microarray study of 10 men and 9 women with facioscapulohumeral
dystrophy, women had higher expression of GRB10 (2.7-fold, P,0.001) and ACVR2B (1.7-fold, P,0.03). If these sex-related
differences in mRNA expression lead to reduced IGF-1 activity and increased myostatin activity, they could contribute to the
sex difference in muscle size.
Citation: Welle S, Tawil R, Thornton CA (2008) Sex-Related Differences in Gene Expression in Human Skeletal Muscle. PLoS ONE 3(1): e1385.
doi:10.1371/journal.pone.0001385
INTRODUCTION
There is sexual dimorphism of skeletal muscle in overall mass, size
of individual fibers, activities of several metabolic enzymes, lipid
content and oxidation, relative expression of different myosin
isoforms, fatigability, and expression of a number of genes [1–9].
Although all types of muscle fibers are larger in men, the sex
difference is especially pronounced in type 2 fibers so that there is
a greater ratio of type 2 fiber mass to type 1 fiber mass in men
[1,5,10]. The sex difference in muscle mass is presumed to be
mediated by higher testosterone levels in men, because of the well
known anabolic effect of testosterone [11–13] and because
estrogens and progestins do not reduce muscle mass [14–17].
The relative enlargement of muscle in males develops after the
pubertal increase in testosterone production. After that, men
require testosterone to maintain a normal muscle mass [11–
13,18,19]. Testosterone, like all steroid hormones, exerts its effects
by influencing gene expression. It has not been established which
genes are responsible for its anabolic effects. While some effects of
testosterone on gene expression might be limited to the period of
rapid muscle growth after puberty, there must be some permanent
effects to maintain the larger muscle mass in men.
There have been few comparisons of broad gene expression
profiles in men and women. Roth et al. reported differences between
men and women in the muscle expression of ,20% of ,1,000
transcriptsthatyieldedreliablesignalsoncDNAarrays[4].Yoshioka
et al. [20] used serial analysis of gene expression (SAGE) to compare
muscle gene expression in male and female mice, but SAGE is better
suited for studying highly-expressed genes, such as those encoding
metabolic and contractile proteins, than for studying the majority of
transcripts that are expressed at lower levels. We have used
comprehensive oligonucleotide arrays to study the effect of aging
on expression profiles of both men and women [21,22], but have not
previously reported the sex differences. The purpose of this report is
to summarize the key features of the sex-related differences in gene
expression in these subjects.
RESULTS
We obtained muscle samples from the vastus lateralis from normal
adult subjects, including 15 men and 15 women 20–75 years old.
To limit variability of activity and diet prior to the biopsies,
subjects were admitted to the University of Rochester General
Clinical Research Center for 3 days, where they were provided a
standard weight-maintaining diet and were instructed not to
perform any activity more strenuous than walking. Table 1 shows
their mean body composition (by dual-energy X-ray absorptiom-
etry) and isometric knee extension strength. The men had more
lean tissue mass overall (mean 41%) and in the legs (mean 48%)
than the women. There did not appear to be a sex difference in
physical fitness—isometric knee extension strength and maximal
oxygen consumption were similar in the men and women when
expressed per kg lean body mass or lean tissue mass of the legs.
Table 1 also shows the expression of genes encoding types 1, 2a,
and 26 myosin heavy chains (MYH). Expression of these genes
was determined by RT-PCR because these highly expressed
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women have a higher ratio of type 1 fiber mass to type 2 fiber
mass, the higher ratio of type 1 MYH to types 2a and 26MYH
was expected. (To avoid confusion, we did not use the official gene
symbols in Table 1; types 1, 2a, and 26fibers express the MYH7,
MYH2, and MYH1 genes, respectively.)
Affymetrix U133A and U133B high-density oligonucleotide
arrays, containing ,45,000 probe sets targeting all known human
mRNAs and expressed sequence tags at the time of UniGene build
133, were used to examine gene expression. After elimination of
probe sets that did not generate signals significantly above cross-
hybridization (‘‘mismatch’’) control oligos, as well as those with
signals too strong to be accurately quantified, there were ,17,000
probe sets included in the analysis. The sex-related differences for
these probe sets are available in a supporting information file (Excel
File S1). The CEL files and GCRMA-normalized data for every
probe set are available from the Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo/) via accession number GSE9676.
The Significance Analysis of Microarrays (SAM) program [23],
which evaluates the distribution of the t statistic with numerous
random permutations of group assignments (male vs. female in this
study), indicated that there were more than 3,000 sex-related
differences when limiting the false discovery rate to 5%. This
method did not account for age as a source of variance, so we used
analysis of variance (ANOVA) as the primary method to rank
genes according to the likelihood that there is a sex difference in
expression after accounting for overall age effects (which have
been reported previously). According to ANOVA there were more
than 2,400 probe sets with a sex difference at P,0.01, more than
800 at P,0.001, and more than 300 at P,0.0001 (Figure 1).
These nominal P values do not account for the fact that 17,000
comparisons were made simultaneously, but by comparison with
the number of differences suggested by SAM it appears that the
proportion of false discoveries at nominal P,0.01 should be very
low.
As expected, the largest sex differences in signal intensity were
observed with Y-chromosome genes and XIST, which mediates
inactivation of one copy of the X chromosome in female cells [24]
(Figure 1).
Table 2 lists the sex differences that stood out in the present
study both in magnitude ($2-fold) and consistency (P,0.0001 by
ANOVA). Presentation of only these genes does not necessarily
mean that these are the most important genes. This short list is
presented to illustrate the fact that genes with various functions are
differentially expressed, and that most of these genes have not been
studied by researchers interested in the regulation of muscle mass.
An expanded list (less stringent P and fold-difference criteria)
would show the same thing.
Two of the genes expressed at higher levels in women, GRB10
and ACVR2B, encode proteins that are in signaling pathways of
growth factors known to regulate muscle mass. The sex difference
in GRB10 expression was especially convincing, demonstrating a
2.3- to 2.5-fold difference with three probe sets as highlighted in
Figure 1 (ACVR2B has only one probe set). The increased insulin
receptor gene expression in women could be related to the higher
GRB10 expression (see Discussion).
Because ofthe potential significanceofGRB10 and ACVR2Bgenes
as regulators of muscle mass, we used quantitative RT-PCR as an
independent method to examine their expression. The HPRT1
transcript was selected as the reference gene on an empirical basis—
HPRT1 expression in these men (18636111 arbitrary units,
mean6SEM) and women (18816138 arbitrary units) was similar
according to the microarray data (this choice does not necessarily
Table 1. Mean6SEM body composition, muscle performance,
and MYH gene expression patterns in 15 men and 15 women
with normal muscles who donated tissue for gene expression
study.
......................................................................
Male Female P
Total body mass (kg) 76.862.9 64.861.8 0.001
Lean body mass (kg) 56.461.6 40.161.3 ,0.001
Left leg lean mass (kg) 9.360.4 6.360.3 ,0.001
Knee extension force/leg lean mass (N/kg) 48634 7 62 0.81
VO2 max/leg lean mass (ml/min/kg) 116671 1 5 66 0.91
type 1 MYH mRNA
a 100611 135616 0.08
type 2a MYH mRNA
a 100677 0 66 0.004
type 26MYH mRNA
a 100620 85618 0.56
a% of MYH mRNA level in average male, normalized to a-actin mRNA
doi:10.1371/journal.pone.0001385.t001
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Figure 1. Volcano plot illustrating statistical significance of sex-
related differences (shown as negative log of the ANOVA P level, so
that the most significant differences are on top) in relation to
magnitude of mean differences (shown as log of the female/male
expression ratio, so that genes expressed at higher levels in women
have positive values and those expressed at higher levels in men
have negative values). The lower panel is a magnified version of part of
the upper panel, excluding the very large differences for Y-chromosome
genes and XIST, which are enclosed in red boxes in the upper panel. The
three solid red circles in the lower panel represent the probe sets for
the GRB10 gene transcript.
doi:10.1371/journal.pone.0001385.g001
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According to this method, GRB10 expression was 2.6-fold greater
in the women (P,0.0001), and ACVR2B expression was 1.6-fold
greater (P,0.01). GRB10/HPRT1 ratios by microarray in individual
subjects correlated closely with these ratios determined by RT-PCR
(r=0.91, P,0.0001). ACVR2B/HPRT1 ratios by microarray and
PCR also correlated well (r=0.69, P,0.01).
We also examined our database of expression profiles of 10 men
and 9 women with facioscapulohumeral dystrophy [25] for a sex
difference in expression of GRB10 and ACVR2B. The women had
higher expression of GRB10 (2.7-fold, P,0.001) and ACVR2B (1.7-
fold, P,0.03).
Two bioinformatics resources, Gene Set Enrichment Analysis
(GSEA) [26] and Expression Analysis Systematic Explorer (EASE)
[27], were used to relate differentially expressed genes to
functional categories. Rather than focusing on the largest
differences among individual genes, GSEA integrates similar
trends in expression levels among multiple genes related to one
another (functionally, by co-regulation in previous experiments, by
chromosomal location, or by similarity of transcription factor
binding domains). According to the GSEA approach, genes
expressed at higher levels in women were enriched (false discovery
rate ,5%) in a Chromosome 6q24 gene set. We have no
explanation for this cluster. Genes expressed at higher levels in
men were enriched in a ‘‘testis-expressed’’ set, with numerous Y-
chromosome genes, and the ‘‘UVB_NHEK2_UP’’ gene set. The
top member of the latter set in the current study was a Y-
chromosome gene, and it is likely that the similarity of genes sets
would not have been statistically significant without inclusion of
this gene.
EASE sorts genes according to Gene Ontology categories. This
program compares a list of ‘‘significant’’ genes to the entire list of
genes included on the array to determine if certain categories are
represented more than expected by chance. Use of very strict
criteria to define differential expression limits the utility of this
approach, so we selected genes with sex differences at nominal
P,0.01 with no fold-difference criterion. With genes expressed at
higher levels in women, there were no categories enriched at
P,0.05 (corrected for multiple tests by the Bonferroni method).
With genes expressed at higher levels in men, there were several
enriched categories (Figure 2). Genes encoding proteins involved
in protein synthesis accounted for enrichment of the ‘‘macromol-
ecule biosynthesis’’ category. Numerous ribosomal protein genes
were the main reason for enrichment of the ‘‘RNA binding’’ and
Table 2. Genes with $2-fold differential expression in muscles of men and women at P,0.0001, excluding XIST and Y-chromosome
genes.
..................................................................................................................................................
gene symbol Fold D Comment/function of gene product
Higher expression in women
CDC42 binding protein kinase beta (DMPK-like) CDC42BPB 4.0 May act as a downstream effector of Cdc42 in cytoskeletal reorganization
Ryanodine receptor 3 RYR3 3.6 Ca
++ release
ADAMTS-like 4 ADAMTSL4 3.5 Member of ADAMTS (a disintegrin and metalloproteinase with
thrombospondin motifs)-like gene family
Insulin receptor INSR 3.4 Insulin signaling
Ubiquitously transcribed tetratricopeptide repeat,
X chromosome
UTX 2.6 Escapes X inactivation
Growth factor receptor bound 10 GRB10 2.4 Inhibits insulin and IGF-1 signaling
Zinc finger protein 462 ZNF462 2.3 Transcription
Nuclear factor I/X NFIX 2.3 Transcription
Calcium/calmodulin-dependent protein kinase
(CaM kinase) II beta
CAMK2B 2.3 Kinase activity increased by exercise
Activin A receptor IIB ACVR2B 2.3 Myostatin signaling
Calmodulin 3 (phosphorylase kinase, delta) CALM3 2.3 Signal transduction
Forkhead box O3 FOXO3 2.2 Transcription
Bromodomain containing 4 BRD4 2.1 Chromatin binding; mitosis
Aldehyde dehydrogenase 4 family, member A1 ALDH4A1 2.0 Catalyzes the second step of the proline degradation pathway
Nuclear factor of kappa light polypeptide gene enhancer
in B-cells inhibitor, alpha
NFKBIA 2.0 Signal transduction
Higher expression in men
Iroquois homeobox protein 3 IRX3 4.5 Transcription
cell division cycle 37 homolog (S. cerevisiae)-like 1 CDC37L1 2.5 May function to regulate the Hsp90-mediated folding of Cdc37-dependent
protein kinases into functional conformations via dimerization with Cdc37
presenilin enhancer 2 homolog (C. elegans) PSENEN 2.3 Required for Notch pathway signaling
Dishevelled associated activator of morphogenesis 2 DAAM2 2.4 Similar to DAAM1, which has higher expression in women (1.7-fold) and is
involved in Wnt/Fz signaling
tumor protein D52 TPD52 2.3 May be involved in calcium-mediated signal transduction and cell
proliferation
transmembrane emp24 domain trafficking protein 2 TMED2 2.2 Protein transport
Cold shock domain protein A CSDA 2.2 Transcription
doi:10.1371/journal.pone.0001385.t002
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PLoS ONE | www.plosone.org 3 January 2008 | Issue 1 | e1385‘‘structural constituent of ribosome’’ categories, and also were a
major part of the ‘‘macromolecule biosynthesis’’ category. Several
translation initiation factor genes also were in the biosynthesis
category. The ‘‘H
+ transporter’’ list was mostly genes encoding
proteins of the electron transport chain and mitochondrial ATP
synthase. These genes also contributed to enrichment of the
‘‘oxidative phosphorylation’’ and ‘‘mitochondrion’’ categories.
Genes encoding mitochondrial ribosomal proteins contributed to
enrichment of both the ‘‘biosynthesis’’ and ‘‘mitochondrion’’
categories.
DISCUSSION
It is well accepted that IGF-1 has an anabolic effect on muscle
[28]. Although IGF1 gene expression in muscle is sensitive to
testosterone depletion or administration in men [18,29], no sex
difference in plasma IGF-1 levels or muscle IGF1 gene expression
has been observed [10]. The microarrays used in the present study
also did not detect any sex difference in IGF1 gene expression in
muscle. However, IGF-1 signaling might be reduced in women
because of their elevated expression of GRB10, which encodes a
protein that interferes with IGF-1 signal transduction [30,31].
GRB10 also interferes with insulin signaling [31,32], in part by
mediating degradation of the insulin receptor [33], but the 3-fold
increase in insulin receptor gene expression in women (Table 2)
could serve to minimize any negative effect on insulin sensitivity
that increased GRB10 expression might have. In contrast, there is
not a sex difference in expression of the IGF-1 receptor according
to the present microarray study and a previous study in which
IGFR gene expression was determined by RT-PCR analysis [10].
Thus, the greater GRB10 expression in women might restrain
IGF-1 signaling and contribute to the sex difference in
muscularity. The plausibility of this hypothesis is supported by
recent studies demonstrating that GRB10 knockout in mice was
associated with increased muscularity [31,34].
Myostatin has a major role in determining muscle size.
Constitutive myostatin knockout in mice leads to a hypermuscular
phenotype caused by an increased number of fibers and fiber
enlargement [35]. Myostatin appears to function similarly in
humans [36]. Post-developmental inhibition of myostatin activity
causes muscle hypertrophy in mice without increasing the number
of muscle fibers [37–39]. Although there is no evidence for
differential expression of myostatin mRNA in men and women
either from the present study or previous analyses by RT-PCR
[40,41], this does not necessarily mean that the myostatin pathway
has the same level of activity in men and women. For example,
myostatin protein levels in muscle are higher in female than male
mice even though mRNA levels are similar in males and females
[42]. Moreover, myostatin activity could differ in men and women
if there is a difference in any of the proteins that process myostatin,
bind to myostatin, or mediate myostatin signal transduction. Here,
we report that a myostatin receptor gene, ACVR2B, is expressed at
a higher level in women. In mice, knockout of either activin A
receptor IIA (ACVR2A)o rACVR2B causes muscle hypertrophy
[38]. Hemizygous knockout of ACVR2B accentuates muscle
growth in ACVR2A-knockout mice, although it has no effect in
mice with normal ACVR2A expression [38]. The microarrays
indicated that the ACVR2A gene is expressed in human muscle,
with no significant difference between men and women. Thus,
understanding the functional significance of higher ACVR2B
expression in women will require elucidation of the relative
importance of ACVR2A and ACVR2B in myostatin signal
transduction in humans, and whether ACVR2B expression is a
limiting factor. It was reported recently that women with different
ACVR2B haplotypes had different levels of quadriceps strength,
although this was not observed in men, and there was no
difference in leg muscle mass as assessed by DEXA [43]. It is not
known whether the polymorphisms in the ACVR2B genes in the
different haplotypes affect ACVR2B expression in muscle.
Because testosterone is assumed to be responsible for the greater
muscle mass in men, an obvious issue is whether it regulates
expression of GRB10 or ACVR2B genes. Consensus androgen
responsive elements [44,45] are not near (within 5 kb) the
transcription start sites of these genes. It must be emphasized that
many, if not most, functional androgen responsive elements differ
in several bases from the consensus motif [46]. Hence it is not
currently possible to prove or rule out by computer algorithms
Figure 2. Summary of functional categories of genes expressed at higher levels in men than in women (nominal P,0.01). The percentage of
genes expressed at a higher level in men that were assigned to the functional categories (rectangular boxes) was higher than would be expected by
chance based on the percentage of all genes in these categories (Bonferroni P,0.05 according to EASE program). The ovals show the numbers of
genes in more specific functional categories, with arrows showing how they relate to the broader categories.
doi:10.1371/journal.pone.0001385.g002
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are no androgen responsive DNA elements regulating these genes
directly, testosterone could influence their expression indirectly by
its effects on expression of other genes. Studies of men undergoing
pharmacologic inhibition of testosterone production would be the
best approach to determine whether these sex differences in gene
expression are mediated by testosterone.
One of the genes listed in Table 2, FOXO3, encodes a forkhead
box transcription factor that can influence muscle catabolism. In
its active non-phosphorylated state, this transcription factor
stimulates expression of the ubiquitin ligase atrogin-1 (also known
as MAFbx or F-box protein 32) [47]. Atrogin-1 is upregulated
under conditions associated with muscle atrophy [48]. Atrogin-
mediated ubiquitination of proteins increases the rate of
proteasomal proteolysis. Although FOXO3 expression was ,2-
fold higher in women than in men, there was no evidence from the
microarray data for increased atrogin-1 expression in women.
Moreover, there is no evidence for increased fractional muscle
protein turnover in women [49–51], suggesting that increased
muscle proteolysis is not responsible for the smaller muscle mass of
women.
Most investigators using microarrays focus on the largest and
most consistent differences in gene expression. However, more
subtle differences in gene expression might have significant
consequences, particularly if several genes involved in the same
pathway are involved. We used the GSEA and EASE methods to
search for sex-related differences in pathways and functional
categories of genes that might not be obvious based on the largest
fold differences or lowest P levels. Given the greater ratio of type 1
muscle fiber mass to type 2 mass in women, one might expect a
tendency for greater expression in women of genes encoding
mitochondrial proteins. However, the opposite trend was ob-
served. There also was a tendency for the men to have higher
expression of ribosomal proteins (both cytosolic and mitochondri-
al) and translation initiation factors. Higher expression of these
genes might support an increased rate of protein synthesis in men.
As mentioned above, men and women have similar fractional
muscle protein breakdown rates. Therefore, men must have a
higher rate of protein synthesis per muscle fiber or else they would
not have a greater protein mass per fiber. (Even though synthesis
per fiber is greater in men, the fractional rate is similar in men and
women because protein mass per muscle fiber is greater in men.)
The GSEA program did not find enrichment in any of the Gene
Ontology categories that were found by the EASE program to be
more highly expressed in men. This discrepancy can be explained
by the difference in the approaches of the two methods. EASE
does not impose a penalty if differences opposite to the overall
trend are present, whereas GSEA does because it takes into
consideration all differences in both directions regardless of the
statistical significance for individual genes. For example, there
were 9 translation initiation factor genes expressed at a higher level
in men (at nominal P,0.01), but there were 4 expressed at a
higher level in women. For some other categories shown in
Figure 2, the ratio of significant effects in men versus women were
22/4 (mitochondrial ribosomal proteins), 17/3 (ribosomal pro-
teins), and 7/2 (lysosomal H
+ transporters).
The functional significance of sex-related differences in mRNA
levels depends on whether they cause differences in protein levels.
Unfortunately, we do not have any more muscle tissue from these
subjects to examine protein levels. We encourage others who are
interested in the sexual dimorphism of muscle to examine mRNA
and protein expression of GRB10, ACVR2B, or other genes that
were differentially expressed in men and women in the present
study.
METHODS
Subjects
Musclewasobtainedbyneedlebiopsy,withlocalanesthesia,from30
subjects with normal muscles [7 young men (21–27 yr old), 8 older
men (65–75 yr old), 7 young women (20–29 yr old), 8 older women
(65–71 yr old)]. Quadriceps strength, maximal oxygen consumption,
and body composition measures were done as described elsewhere
[21,22]. All subjects were fully informed of risks and gave written
consent for participation. The study was approved by the University
of Rochester Research Subjects Review Board.
Expression profiles
Affymetrix U133A and U133B GeneChip arrays were used to
examine gene expression. Details of RNA extraction and
microarray methods have been described elsewhere [21,22]. The
gene expression database was examined for differential expression
in men and women after re-calculating expression scores with the
GCRMA method [52] as implemented by ArrayAssist Lite
software (Stratagene, Version 3.3). This method was chosen after
comparing it the standard Affymetrix method, a modified version
of the Affymetrix comparison analysis algorithm that was used for
our analyses of age-related differences [53], and RMA [54],
because it had the best performance in accounting for non-specific
hybridization (expression scores in women close to zero for Y
chromosome genes; in men close to zero for XIST gene) and had
the highest correlation with quantitative RT-PCR for mean age-
related differences across 8 different transcripts (r=0.83). Probe
sets with high (P.0.10) ‘‘detection P’’ values (Affymetrix
algorithm) for more than half of the arrays from the group with
higher mean expression were excluded from further analysis,
which reduces the number of false positives [53,55]. Probe sets
that were saturated by very abundant transcripts also were
excluded from the analysis. ANOVA for the probe sets that passed
these filters was done with a Visual Basic script to calculate F
ratios, which were exported to a Microsoft Excel spreadsheet for
determination of nominal P values. Excel also was used for
computation of mean differences between men and women. The
SAM program (Version 2.21), which runs within Excel, was
provided by Stanford University [23]. The GSEA program
(Version 2.0) was provided by the Broad Institute [26]. The
EASE program (Version 2.0) was provided by the National
Institutes of Health [27].
Quantitative RT-PCR
Expression of the MYH genes was determined with a competitive
PCR method [56]. This was done prospectively, so RNA was
available from all subjects for these assays. GRB10 and ACVR2B
transcripts were examined by quantitative real time PCR. These
assays were done after the microarray analyses were completed, at
which time RNA samples were available from 8 men and 7
women. HPRT1 mRNA served as the reference transcript. RNA
was treated with DNase I, then reverse transcribed by MMLV
reverse transcriptase with oligo-dT as the primer. Real-time PCR
quantification of cDNAs was done in triplicate reactions with the
Applied Biosystems (ABI) Prism 7900HT Sequence Detection
System. Primer and probe sets for TaqMan assays were purchased
from ABI (for GRB10, assay number Hs00959287_m1; for
ACVR2B, Hs00609603_m1; for HPRT1, catalog number
4333768F ). The unit of measure in these assays is the difference
in cycle threshold (DCt) between the cDNA of interest and the
reference cDNA, with an increase in DCt of one cycle reflecting a
decrease of ,2-fold in the GRB10/HPRT1 or ACVR2B/HPRT1
ratio.
Muscle Gene Expression
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Excel File S1 Sex differences for all transcripts detected in
muscle. Affymetrix probe set IDs, female/male expression ratios, P
values (from ANOVA), and gene names and IDs for all transcripts
detected in skeletal muscle.
Found at: doi:10.1371/journal.pone.0001385.s001 (3.07 MB
XLS)
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